Inequalities in the omission of axillary dissection in sentinel lymph node positive patients in the Netherlands: Innovative hospitals are early adopters of a de‐escalating approach

Abstract During the last decade completion axillary lymph node dissection (cALND) was gradually omitted in sentinel lymph node positive (SLN+) breast cancer patients. However, adoption varies among hospitals. We analyzed factors associated with the omission of cALND in all Dutch SLN+ patients. As one of the focus hospital‐related factors we defined “innovative” as the percentage of gene‐expression profile (GEP) deployment within the indicated group of patients per hospital as a proxy for early adoption of innovations. cT1‐2N0M0 SLN+ patients treated between 2011 and 2018 were selected from the... Mehr ...